Onco-Innovations CMO Details Dual-Mechanism PNKP Inhibitor ONC010
Key Takeaways
- •Onco-Innovations' lead candidate ONC010 is designed to inhibit PNKP, an enzyme that plays a key role in repairing DNA damage.
- •The company aims to achieve tumor selectivity through synthetic lethality, restricting the drug's lethal effects to cancer cells deficient in PTEN or SHP-1, alongside nanoparticle delivery that concentrates it in tumor tissue.
- •Preclinical studies at the University of Alberta showed the nano-formulated inhibitor exhibited antitumor activity as a single agent, was tolerated at the doses tested, and extended survival compared with control groups.
- •Onco-Innovations holds an exclusive worldwide license to patented PNKP inhibition technology and is preparing a first-in-human clinical program for ONC010.
- •The company's claims regarding selectivity and tolerability remain subject to confirmation in human clinical trials.
Onco-Innovations Limited (CBOE CA: ONCO) (OTCQB: ONNVF) (Frankfurt: W1H, WKN: A3EKSZ) is developing ONC010, a lead drug candidate designed to target polynucleotide kinase phosphatase (PNKP), an enzyme involved in DNA repair. In a recent episode of the IBN BioMedWire Podcast, the company’s Chief Medical Officer, Dr. Islam Mohamed, discussed the scientific rationale for the program and Onco-Innovations’ development strategy.
Dr. Mohamed identified two selectivity mechanisms intended to distinguish ONC010. The first is synthetic lethality, which is designed to restrict the drug’s lethal effects to cancer cells that have lost PTEN or SHP-1. The second is nanoparticle delivery, which is intended to concentrate the drug in tumor tissue. According to the company, combining these mechanisms could support activity against cancer cells while limiting damage to healthy cells.
Preclinical research conducted at the University of Alberta produced results that the company described as promising. Dr. Mohamed said the nano-formulated PNKP inhibitor demonstrated single-agent antitumor activity, was tolerated at the doses tested, and prolonged survival compared with control groups. The findings support further evaluation of ONC010 as a targeted treatment for cancers with specific genetic vulnerabilities, although results from human studies will be needed to assess whether the preclinical observations translate clinically.
Onco-Innovations holds an exclusive worldwide license to patented technology directed to the therapeutic inhibition of PNKP. The company describes PNKP as a novel clinical target within the DNA damage response. It is planning a first-in-human clinical program for ONC010, which would mark the next stage in the drug candidate’s development.
The program is focused on a potential treatment approach for oncology patients with limited options. By targeting PNKP and using nanoparticle delivery, Onco-Innovations is investigating whether ONC010 can provide selective activity while reducing side effects associated with some traditional chemotherapy approaches. The company’s claims regarding selectivity and tolerability remain subject to confirmation in clinical trials.
The BioMedWire podcast interview outlined the company’s scientific approach and strategic direction. The full press release is available at . Company news relating to ONNVF is available through its newsroom at . Additional information about BioMedWire is available at , with terms of use and disclaimers at . The original report was published by Citybuzz at https://www.citybuzz.co/2026/09/10/onco-innovations-cmo-highlights-dual-mechanism-of-pnkp-inhibitor-onc010-in-biomedwire-podcast/ .
